代谢组学在冠心病痰瘀互结证诊断中的研究进展

在冠心病痰瘀互结证的临床治疗过程中,有创的冠状动脉造影术及其副作用严重限制了此方法对冠心病的大规模人群筛查和早期风险预测,而冠心病痰瘀互结证的广泛性和难治性以及中医辨证的主观性又会影响中医药辨治冠心病的疗效。代谢组学的出现可以解决这一难题,并把精准医学的理念渗透到传统中医诊疗的全过程。文章通过对知网、万方、维普及Pubmed、Elsevier等数据库中有关代谢组学在冠心病研究中的国内外文献进行总结和分析,发现冠心病诊断主要与磷脂代谢、能量代谢、不饱和脂肪酸及其代谢物以及肠道微生物代谢等关系密切,冠心病痰瘀互结证涉及的代谢通路主要包括糖脂代谢、能量代谢等。

Metabolomics in the diagnosis of coronary heart disease with phlegm and blood stasis syndrome

Invasive coronary angiography and its side effects severely limit the screening and early risk prediction of large-scale coronary heart disease in the course of clinical treatment of coronary heart disease with phlegm and blood stasis syndrome.The extensiveness and intractability of coronary heart disease with phlegm and blood stasis syndrome and the subjectivity of differentiation of syndromes and treatment have affected the efficacy of Chinese medicine in treating coronary heart disease.The emergence of metabolomics solved this problem and penetrated the concept of precision medicine into the whole process of traditional Chinese medicine diagnosis and treatment. Through the research and study on the literature of metabolomics in the databases of Zhiwang, Wanfang, Weipu,Pubmed, Elsevier, etc. in the application of coronary heart disease, it was found that the diagnosis of coronary heart disease involves phospholipid metabolism, energy metabolism, metabolism of unsaturated fatty acids and their metabolites and intestinal microflora. The metabonomics of coronary heart disease syndrome of phlegm and blood stasis involves metabolism of glucose and lipids, energy metabolism and so on.